Comment on “Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review” | Zendy

George F. Kroker | Zendy; Vijay K. Sabnis | Zendy; Mary S. Morris | Zendy; James C. Thompson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comment on “Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review”

Author(s) -

George F. Kroker,

Vijay K. Sabnis,

Mary S. Morris,

James C. Thompson

Publication year - 2012

Publication title -

journal of allergy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.39

H-Index - 3

eISSN - 1687-9791

pISSN - 1687-9783

DOI - 10.1155/2012/969861

Subject(s) - sublingual immunotherapy , medicine , slit , dosing , immunotherapy , sublingual administration , desensitization (medicine) , anaphylactic reactions , allergy , intensive care medicine , anaphylaxis , pharmacology , immunology , immune system , psychology , receptor , neuroscience

Numerous sublingual immunotherapy studies have shown efficacy using a wide variety of dosing regimens. Despite a few grade III and one anaphylactic reaction due to a patient over-dose, there have been no fatal reactions resulting from sublingual immunotherapy treatment. Although safer than SCIT, SLIT is still immunotherapy. Special consideration should be given to what will ensure the highest level of safety for the patient given his or her history, exam and allergy test results. Dosing levels for sublingual immunotherapy should be based on what is therapeutically effective for each individual patient and adjusted accordingly throughout the treatment course.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research